Bioventus Inc.BVSNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank58
3Y CAGR-20.2%
5Y CAGR+1.6%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-20.2%/yr
vs +31.0%/yr prior
5Y CAGR
+1.6%/yr
Recent deceleration
Acceleration
-51.2pp
Decelerating
Percentile
P58
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$12.11M-11.2%
2024$13.64M+1.4%
2023$13.45M-43.6%
2022$23.85M+25.3%
2021$19.04M+70.0%
2020$11.20M+1.3%
2019$11.05M+36.6%
2018$8.10M-0.0%
2017$8.10M+2.5%
2016$7.90M-